All publications

Export 169 results:
Author [ Title(Asc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin CA, Phillips AN, Allen E., Pillay D.  2008.  What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT.  2018.  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.
Gupta R.K, Hill A., Sawyer A.W, Cozzi-Lepri A, von Wyl V., Yerly S, Lima V.D, Günthard HF, Gilks C., Pillay D.  2009.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.
Jose S., Quinn K., Dunn DT, Cox A., Sabin CA, Fidler S.  2016.  Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Med. 17:368-72.
Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2005.  Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, O’Shea S, Tong W, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral genotype in subtype C significantly influences plasma viral load. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2013.  Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.
Gifford RJM, Pillay D, UK HIV Drug Resistance Database.  2005.  Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.
Stirrup O, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie N, Dunn D, Cohort UKHIVDrug R.  2019.  Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.
Pillay D, Green H, UK HIV Drug Resistance Database.  2003.  The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.
Dunn DT, Pillay D.  2007.  UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.
Chilton DN, Harrison LJ, Green H, Lattimore S, Delpech V, Pillay D.  2008.  Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.
Tostevin A, White E, Croxford S, Delpech V, Williams I, Dunn DT, UK HIV Drug Resistance Database.  2015.  Trends in transmitted drug resistance to HIV-1 in the UK since 2010. British HIV Association Conference (BHIVA) 2015.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Brown A, Delpech V, Dunn DT, Leigh Brown A.  2016.  Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis. 213:1410-8.
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT.  2011.  Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2012.  Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Asboe D, Gascuel O, Hue S.  2014.  Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.
Cane P A, Chrystie I, Dunn DT, Evans B., Geretti AM, Green H, Phillips AN, Pillay D, Porter K, Pozniak A et al..  2005.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.
Dunn DT, Green H, Fearnhill E.  2007.  Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.